216 related articles for article (PubMed ID: 16079393)
1. Prenylation-defective human connexin32 mutants are normally localized and function equivalently to wild-type connexin32 in myelinating Schwann cells.
Huang Y; Sirkowski EE; Stickney JT; Scherer SS
J Neurosci; 2005 Aug; 25(31):7111-20. PubMed ID: 16079393
[TBL] [Abstract][Full Text] [Related]
2. Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.
Scherer SS; Xu YT; Messing A; Willecke K; Fischbeck KH; Jeng LJ
J Neurosci; 2005 Feb; 25(6):1550-9. PubMed ID: 15703409
[TBL] [Abstract][Full Text] [Related]
3. The effects of a dominant connexin32 mutant in myelinating Schwann cells.
Jeng LJ; Balice-Gordon RJ; Messing A; Fischbeck KH; Scherer SS
Mol Cell Neurosci; 2006 Jul; 32(3):283-98. PubMed ID: 16790356
[TBL] [Abstract][Full Text] [Related]
4. Altered gene expression in Schwann cells of connexin32 knockout animals.
Nicholson SM; Gomès D; de Néchaud B; Bruzzone R
J Neurosci Res; 2001 Oct; 66(1):23-36. PubMed ID: 11598999
[TBL] [Abstract][Full Text] [Related]
5. Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects.
Sargiannidou I; Vavlitou N; Aristodemou S; Hadjisavvas A; Kyriacou K; Scherer SS; Kleopa KA
J Neurosci; 2009 Apr; 29(15):4736-49. PubMed ID: 19369543
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal gene therapy in mouse models expressing CMT1X mutations.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Lapathitis G; Sargiannidou I; Christodoulou C; Kleopa KA
Hum Mol Genet; 2018 Apr; 27(8):1460-1473. PubMed ID: 29462293
[TBL] [Abstract][Full Text] [Related]
7. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease.
Sargiannidou I; Kagiava A; Bashiardes S; Richter J; Christodoulou C; Scherer SS; Kleopa KA
Ann Neurol; 2015 Aug; 78(2):303-16. PubMed ID: 26010264
[TBL] [Abstract][Full Text] [Related]
8. Connexin32-null mice develop demyelinating peripheral neuropathy.
Scherer SS; Xu YT; Nelles E; Fischbeck K; Willecke K; Bone LJ
Glia; 1998 Sep; 24(1):8-20. PubMed ID: 9700485
[TBL] [Abstract][Full Text] [Related]
9. Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X.
Kyriakoudi S; Sargiannidou I; Kagiava A; Olympiou M; Kleopa KA
Hum Mol Genet; 2017 May; 26(9):1622-1633. PubMed ID: 28334782
[TBL] [Abstract][Full Text] [Related]
10. Connexin32 and X-linked Charcot-Marie-Tooth disease.
Bone LJ; Deschênes SM; Balice-Gordon RJ; Fischbeck KH; Scherer SS
Neurobiol Dis; 1997; 4(3-4):221-30. PubMed ID: 9361298
[TBL] [Abstract][Full Text] [Related]
11. The role of the gap junction protein connexin32 in the pathogenesis of X-linked Charcot-Marie-Tooth disease.
Scherer SS; Bone LJ; Deschênes SM; Abel A; Balice-Gordon RJ; Fischbeck KH
Novartis Found Symp; 1999; 219():175-85; discussion 185-7. PubMed ID: 10207904
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of X-linked Charcot-Marie-Tooth disease.
Kleopa KA; Scherer SS
Neuromolecular Med; 2006; 8(1-2):107-22. PubMed ID: 16775370
[TBL] [Abstract][Full Text] [Related]
13. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?
Kleopa KA; Abrams CK; Scherer SS
Brain Res; 2012 Dec; 1487():198-205. PubMed ID: 22771394
[TBL] [Abstract][Full Text] [Related]
14. Cellular mechanisms of connexin32 mutations associated with CNS manifestations.
Kleopa KA; Yum SW; Scherer SS
J Neurosci Res; 2002 Jun; 68(5):522-34. PubMed ID: 12111842
[TBL] [Abstract][Full Text] [Related]
15. Connexin channels in Schwann cells and the development of the X-linked form of Charcot-Marie-Tooth disease.
Ressot C; Bruzzone R
Brain Res Brain Res Rev; 2000 Apr; 32(1):192-202. PubMed ID: 10751670
[TBL] [Abstract][Full Text] [Related]
16. Connexin32 is a myelin-related protein in the PNS and CNS.
Scherer SS; Deschênes SM; Xu YT; Grinspan JB; Fischbeck KH; Paul DL
J Neurosci; 1995 Dec; 15(12):8281-94. PubMed ID: 8613761
[TBL] [Abstract][Full Text] [Related]
17. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
Kagiava A; Karaiskos C; Richter J; Tryfonos C; Jennings MJ; Heslegrave AJ; Sargiannidou I; Stavrou M; Zetterberg H; Reilly MM; Christodoulou C; Horvath R; Kleopa KA
Gene Ther; 2021 Nov; 28(10-11):659-675. PubMed ID: 33692503
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of X-linked Charcot-Marie-Tooth disease: differential effects of two mutations in connexin 32.
Abrams CK; Freidin M; Bukauskas F; Dobrenis K; Bargiello TA; Verselis VK; Bennett MV; Chen L; Sahenk Z
J Neurosci; 2003 Nov; 23(33):10548-58. PubMed ID: 14627639
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling studies in regenerating nerves in a mouse model for CMT1X: uninjured Cx32-knockout peripheral nerves display expression profile of injured wild type nerves.
Freidin M; Asche-Godin S; Abrams CK
Exp Neurol; 2015 Jan; 263():339-49. PubMed ID: 25447941
[TBL] [Abstract][Full Text] [Related]
20. Two new mouse models of Gjb1-associated Charcot-Marie-Tooth disease type 1X.
Tadenev ALD; Hatton CL; Pattavina B; Mullins T; Schneider R; Bogdanik LP; Burgess RW
J Peripher Nerv Syst; 2023 Sep; 28(3):317-328. PubMed ID: 37551045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
